Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer.
Tseng KY, Yang MY, Chen WS, Jiang JK, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Yang YW, Lin YZ, Chang CY, Teng HW.
Tseng KY, et al. Among authors: cheng hh.
Int J Colorectal Dis. 2024 Dec 4;39(1):195. doi: 10.1007/s00384-024-04767-9.
Int J Colorectal Dis. 2024.
PMID: 39630293
Free PMC article.